Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 30:13:894770.
doi: 10.3389/fimmu.2022.894770. eCollection 2022.

Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study

Hannah W Kimingi  1   2 , Ann W Kinyua  1 , Nicole A Achieng  1 , Kennedy M Wambui  1   3 , Shaban Mwangi  1 , Roselyne Nguti  1   2 , Cheryl A Kivisi  2   4 , Anja T R Jensen  5 , Philip Bejon  1   6 , Melisa C Kapulu  1   6 , Abdirahman I Abdi  1   4 , Samson M Kinyanjui  1   4   6   7 ; CHMI-SIKA Study Team
Collaborators, Affiliations

Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study

Hannah W Kimingi et al. Front Immunol. .

Abstract

Background: Plasmodium falciparum variant surface antigens (VSAs) contribute to malaria pathogenesis by mediating cytoadhesion of infected red blood cells to the microvasculature endothelium. In this study, we investigated the association between anti-VSA antibodies and clinical outcome in a controlled human malaria infection (CHMI) study.

Method: We used flow cytometry and ELISA to measure levels of IgG antibodies to VSAs of five heterologous and one homologous P. falciparum parasite isolates, and to two PfEMP1 DBLβ domains in blood samples collected a day before the challenge and 14 days after infection. We also measured the ability of an individual's plasma to inhibit the interaction between PfEMP1 and ICAM1 using competition ELISA. We then assessed the association between the antibody levels, function, and CHMI defined clinical outcome during a 21-day follow-up period post infection using Cox proportional hazards regression.

Results: Antibody levels to the individual isolate VSAs, or to two ICAM1-binding DBLβ domains of PfEMP1, were not associated with a significantly reduced risk of developing parasitemia or of meeting treatment criteria after the challenge after adjusting for exposure. However, anti-VSA antibody breadth (i.e., cumulative response to all the isolates) was a significant predictor of reduced risk of requiring treatment [HR 0.23 (0.10-0.50) p= 0.0002].

Conclusion: The breadth of IgG antibodies to VSAs, but not to individual isolate VSAs, is associated with protection in CHMI.

Keywords: CHMI; ICAM1; PfEMP1; Plasmodium falciparum; anti-VSA antibodies; antibody breadth; malaria; variant surface antigens.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Anti-VSA antibodies response and malaria endemicity. (A) The median and interquartile range of anti-VSA antibodies levels (expressed as log median fluorescent intensity) against the panel of isolates. (B) Comparison of anti-VSA IgGs (expressed as log median fluorescent intensity) among individuals from low and high malaria transmission areas. (**** - P-value = <0.0001).
Figure 2
Figure 2
Kaplan Meier survival analysis of time to treatment stratified by individuals’ breadth of anti-VSA antibodies at day C-1. The dotted line denotes the median survival time where the survival probability is below 50%. Medium breadth score: HR= 0.38(95%CI 0.21-0.67, p=0.0008). High breadth score: HR= (0.08(95%CI 0.03-0.24,p=<0.0001).
Figure 3
Figure 3
Change in heterologous anti-VSA antibodies levels after the challenge. Anti-VSA antibodies to the test isolates a day before and on day 14 after the challenge stratified by: (A) treatment outcome and (B) parasitaemia (*- P<0.05).
See this image and copyright information in PMC

References

    1. WHO . World Malaria Report 2021 (2021). Available at: https://www.who.int/teams/global-malaria-programme/reports/world-malaria....
    1. Nkumama IN, O'Meara WP, Osier FHA. Changes in Malaria Epidemiology in Africa and New Challenges for Elimination. Trends Parasitol (2017) 33(2):128–40. doi: 10.1016/j.pt.2016.11.006 - DOI - PMC - PubMed
    1. Liu N. Insecticide Resistance in Mosquitoes: Impact, Mechanisms, and Research Directions. Annu Rev Entomol (2015) 60:537–59. doi: 10.1146/annurev-ento-010814-020828 - DOI - PubMed
    1. Cator LJ, Lynch PA, Thomas MB, Read AF. Alterations in Mosquito Behaviour by Malaria Parasites: Potential Impact on Force of Infection. Malar J (2014) 13:164. doi: 10.1186/1475-2875-13-164 - DOI - PMC - PubMed
    1. Rosenthal PJ. Artemisinin Resistance Outside of Southeast Asia. Am J Trop Med Hyg (2018) 99(6):1357–9. doi: 10.4269/ajtmh.18-0845 - DOI - PMC - PubMed

Publication types